Cartesian Therapeutics, Inc.
RNAC
株式のランク
#18194
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
株価
$6.44
最終同期: 2026-10-21
時価総額
$194.84M
変化（1日）
0.70%
変化（1年）
865.08%
国
US
取引 Cartesian Therapeutics, Inc. (RNAC)
カテゴリー
Healthcare
Cartesian Therapeutics, Inc.（RNAC）の株価履歴
終値の最高値: $0.79 （2023-12-01）
終値の最安値: $14.00 （2016-06-01）
終値の最安値: $14.00 （2016-06-01）
Cartesian Therapeutics, Inc. の株価履歴（2016 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2023 | -33.64% |
| 2022 | -62.77% |
| 2021 | 0.01% |
| 2020 | 73.71% |
| 2019 | -58.81% |
| 2018 | -55.20% |
| 2017 | -51.08% |
| 2016 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.24 | -4.19% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
